Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ABSK061

Phase 2Small molecule

AAbbisko Therapeutics Co, Ltd

ABSK061 is one of 56 small molecule programs targeting Achondroplasia. It is currently in Phase 2.

3

Indications

4

Total Trials

3

Active Trials

55

Competitors

Pipeline

Status by Indication[3][1]

Indication

AchondroplasiaNot yet recruiting

Phase 2Recruiting

Patients With Advanced Solid TumorsRecruiting

AchondroplasiaPhase 2

Not yet recruiting

Phase 2Phase 2

Recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Eloxatin

Tecentriq

Camptosar

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Lazcluze

Johnson & Johnson

Erbitux

Tuoyi

CCoherus Oncology, Inc.

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Phase 2

NCT06632262

Q1 2031

Phase 1/2Not yet recruiting

Achondroplasia

NCT07297875

Clinical

Trials by Indication[1]

Phase 21 trial

A Phase 2 Clinical Study of ABSK061 and ABSK043

Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 2·NCT06632262·202 enrolled

Patients With Advanced Solid Tumors1 trial

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT05244551·85 enrolled

Achondroplasia1 trial

A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Not yet recruiting·AAbbisko Therapeutics Co, Ltd·Phase 1/2·NCT07297875·110 enrolled

Unspecified1 trial

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single or Multiple Oral Doses of ABSK061 Mini-tablets and to Evaluate the Effect of Soft Food With ABSK061 Mini-tablets on Its Pharmacokinetic Profile in Healthy Adult Participants

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT07007546·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ABSK061. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABSK061 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABSK061. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abbisko Therapeutics Co, Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAbbisko Therapeutics Co, Ltd

Related News